{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:24:55Z","timestamp":1769523895925,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment with high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (aHSCT) is an intensive treatment option for patients with severe forms of systemic sclerosis (SSc). Even though associated with a high treatment related mortality, the results in this high-risk population are generally favourable. The knowledge on the potential mechanism of action of this therapy and how it can improve patients with SSc is crucial to better select the right patients for aHSCT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a monocentric retrospective study from T\u00fcbingen, Germany, including 32 patients who underwent aHSCT. Peripheral blood samples were analysed for different lymphocyte subsets at various timepoints before and after aHSCT. Patients were divided into responders and non-responders according to the modified Rodnan skin score and lung function test in the three years following aHSCT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Responders showed significantly lower levels of cluster of differentiation (CD)4 positive T cells in the first months after aHSCT (month 1 and 3), B cells (month 3 and 6 after aHSCT) and natural killer cells (month 1). Mantel-cox test showed a significant deviation of the probability curves, i.e. patients with lower CD4\u2009+\u2009T cells and natural killer cells one month and B cells after 3 months after stem cell transplantation had a higher probability to belong to the responder group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Taken together, this study supports the theory that a profound CD4\u2009+\u2009T cell and B cell lymphopenia is important for patients with SSc to achieve a sustained response after aHSCT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-024-03300-1","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T06:02:30Z","timestamp":1710914550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patients with systemic sclerosis and low CD4 numbers after autologous stem cell transplantation have a favorable outcome"],"prefix":"10.1186","volume":"26","author":[{"given":"Ann-Christin","family":"Pecher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhild","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Koetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wichard","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Wirths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg Christoph","family":"Henes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"issue":"11","key":"3300_CR1","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897\u2013905.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3300_CR2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012;51(6):1017\u201326.","journal-title":"Rheumatology (Oxford)"},{"issue":"1 Suppl","key":"3300_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbmt.2009.10.034","volume":"16","author":"KM Sullivan","year":"2010","unstructured":"Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transpl. 2010;16(1 Suppl):48\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"3300_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2009.013458","volume":"95","author":"D Farge","year":"2010","unstructured":"Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune diseases. Haematologica. 2010;95(2):284\u201392.","journal-title":"Haematologica"},{"issue":"6","key":"3300_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/BOR.0b013e32834aa45f","volume":"23","author":"RK Burt","year":"2011","unstructured":"Burt RK, Milanetti F. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status. Curr Opin Rheumatol. 2011;23(6):519\u201329.","journal-title":"Curr Opin Rheumatol"},{"issue":"9790","key":"3300_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378(9790):498\u2013506.","journal-title":"Lancet"},{"issue":"2","key":"3300_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3899\/jrheum.110868","volume":"39","author":"JC Henes","year":"2012","unstructured":"Henes JC, Schmalzing M, Vogel W, Riemekasten G, Fend F, Kanz L, et al. Optimization of autologous stem cell transplantation for systemic sclerosis -- a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol. 2012;39(2):269\u201375.","journal-title":"J Rheumatol"},{"issue":"2","key":"3300_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2019.230128","volume":"106","author":"J Henes","year":"2021","unstructured":"Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. 2021;106(2):375\u201383.","journal-title":"Haematologica"},{"issue":"1","key":"3300_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41409-020-0978-2","volume":"56","author":"RK Burt","year":"2021","unstructured":"Burt RK, Han X, Quigley K, Arnautovic I, Shah SJ, Lee DC, et al. Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days. Bone Marrow Transpl. 2021;56(1):50\u20139.","journal-title":"Bone Marrow Transpl"},{"issue":"24","key":"3300_CR10","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490\u20138.","journal-title":"JAMA"},{"issue":"1","key":"3300_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe Scleroderma. N Engl J Med. 2018;378(1):35\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"3300_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/ard.2007.082495","volume":"68","author":"I Miniati","year":"2009","unstructured":"Miniati I, Guiducci S, Conforti ML, Rogai V, Fiori G, Cinelli M, et al. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis. 2009;68(1):94\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3300_CR13","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1371\/journal.pone.0001452","volume":"3","author":"JN Fleming","year":"2008","unstructured":"Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE. 2008;3(1):e1452.","journal-title":"PLoS ONE"},{"issue":"9","key":"3300_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.0000000000003660","volume":"88","author":"RA Nash","year":"2017","unstructured":"Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9):842\u201352.","journal-title":"Neurology"},{"issue":"6","key":"3300_CR15","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1002\/art.21908","volume":"54","author":"RA Nash","year":"2006","unstructured":"Nash RA, McSweeney PA, Nelson JL, Wener M, Georges GE, Langston AA, et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum. 2006;54(6):1982\u20136.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"3300_CR16","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1182\/blood.V88.9.3621.bloodjournal8893621","volume":"88","author":"HH Euler","year":"1996","unstructured":"Euler HH, Marmont AM, Bacigalupo A, Fastenrath S, Dreger P, Hoffknecht M, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood. 1996;88(9):3621\u20135.","journal-title":"Blood"},{"key":"3300_CR17","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.3389\/fimmu.2018.02602","volume":"9","author":"KCR Malmegrim","year":"2018","unstructured":"Malmegrim KCR, Lima-Junior JR, Arruda LCM, de Azevedo JTC, de Oliveira GLV, Oliveira MC. Autologous hematopoietic stem cell transplantation for Autoimmune diseases: from mechanistic insights to biomarkers. Front Immunol. 2018;9:2602.","journal-title":"Front Immunol"},{"issue":"5","key":"3300_CR18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/art.21036","volume":"52","author":"D Farge","year":"2005","unstructured":"Farge D, Henegar C, Carmagnat M, Daneshpouy M, Marjanovic Z, Rabian C, et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum. 2005;52(5):1555\u201363.","journal-title":"Arthritis Rheum"},{"key":"3300_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fimmu.2018.00767","volume":"9","author":"L Lutter","year":"2018","unstructured":"Lutter L, Spierings J, van Rhijn-Brouwer FCC, van Laar JM, van Wijk F. Resetting the T cell compartment in Autoimmune diseases with Autologous hematopoietic stem cell transplantation: an update. Front Immunol. 2018;9:767.","journal-title":"Front Immunol"},{"issue":"7","key":"3300_CR20","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s10067-021-05665-z","volume":"40","author":"K Melissaropoulos","year":"2021","unstructured":"Melissaropoulos K, Daoussis D. B cells in systemic sclerosis: from pathophysiology to treatment. Clin Rheumatol. 2021;40(7):2621\u201331.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"3300_CR21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1136\/ard.62.9.904","volume":"62","author":"G Valentini","year":"2003","unstructured":"Valentini G, D\u2019Angelo S, Della Rossa A, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis. 2003;62(9):904\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3300_CR22","first-page":"451","volume":"56","author":"J Henes","year":"2017","unstructured":"Henes J, Glaeser L, Kotter I, Vogel W, Kanz L, Klein R. Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. Rheumatology (Oxford). 2017;56(3):451\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3300_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0388-5","volume":"10","author":"D Farge","year":"2017","unstructured":"Farge D, Arruda LC, Brigant F, Clave E, Douay C, Marjanovic Z, et al. Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. J Hematol Oncol. 2017;10(1):21.","journal-title":"J Hematol Oncol"},{"key":"3300_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/asheducation-2015.1.215","volume":"2015","author":"MR van den Brink","year":"2015","unstructured":"van den Brink MR, Velardi E, Perales MA. Immune reconstitution following stem cell transplantation. Hematol Am Soc Hematol Educ Program. 2015;2015:215\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3300_CR25","doi-asserted-by":"crossref","unstructured":"Porrata LF, Litzow MR, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc. 2001;76(4):407\u201312.","DOI":"10.1016\/S0025-6196(11)62388-4"},{"key":"3300_CR26","doi-asserted-by":"crossref","unstructured":"Hissaria P, Lester S, Hakendorf P, Woodman R, Patterson K, Hill C, et al. Survival in scleroderma: results from the population-based South Australian Register. Intern Med J. 2011;41(5):381\u201390.","DOI":"10.1111\/j.1445-5994.2010.02281.x"},{"issue":"4","key":"3300_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cyto.b.21020","volume":"82","author":"JC Andreu-Ballester","year":"2012","unstructured":"Andreu-Ballester JC, Garcia-Ballesteros C, Benet-Campos C, Amigo V, Almela-Quilis A, Mayans J, et al. Values for alphabeta and gammadelta T-lymphocytes and CD4+, CD8+, and CD56\u2009+\u2009subsets in healthy adult subjects: assessment by age and gender. Cytometry B Clin Cytom. 2012;82(4):238\u201344.","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"3300_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3109\/03009742.2011.606788","volume":"41","author":"P Szodoray","year":"2012","unstructured":"Szodoray P, Varoczy L, Papp G, Barath S, Nakken B, Szegedi G, et al. Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases. Scand J Rheumatol. 2012;41(2):110\u20135.","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"3300_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/23971983231188232","volume":"8","author":"YH Chiu","year":"2023","unstructured":"Chiu YH, Drijver A, Admiraal R, van Rhenen A, Nierkens S, van Laar JM, et al. Anti-thymocyte globulin exposure in patients with diffuse cutaneous systemic sclerosis undergoing autologous haematopoietic stem cell transplantation. J Scleroderma Relat Disord. 2023;8(3):241\u20136.","journal-title":"J Scleroderma Relat Disord"},{"issue":"2","key":"3300_CR30","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","volume":"9","author":"R Admiraal","year":"2022","unstructured":"Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y, et al. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol. 2022;9(2):e111\u2013e20.","journal-title":"Lancet Haematol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03300-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T06:07:53Z","timestamp":1710914873000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3300"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03300-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective analysis was approved by the institutional review board of the Eberhard-Karls-University, Tuebingen, Germany (IRB approval number 348\/2016BO2) to be in accordance with the ethical standards and with the Helsinki Declaration. The data used is considered anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A (no identifiable information is published).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}